Author

Meixia Hu

Observed names: M. Hu, M.X. HU

Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University

Observed institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University

ORCID: 0009-0000-5192-6733

Observed ORCID: 0009-0000-5192-6733

OpenAlex ID: A5069349208

Social Support and Posttraumatic Growth among Postoperative Patients with Breast Cancer: A Latent Profile and Moderated Mediation Analysis

2023 · Yingxuan Gu, Fenggui Bie, et al. · Perspectives In Psychiatric Care · 15

Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.

2020 · W.P. LI, T. ZHU, et al. · Neoplasma · 9

DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

2021 · Mei Yang, Yanhui Fan, et al. · EBioMedicine · 8

Abstract PS8-29: Rare variants in the germline genome holistically determine receptor-independent Her2 signaling pathway activation and immune suppression, shaping pathological type and risk of HER2-negative breast cancer

2021 · Mei Yang, Yanhui Fan, et al. · Cancer Research

Treatment of Advanced Breast Cancer with Chinese Medicinal Herbs of Fei Decoction: A Case Report

2014 · G.M. Lv, M. Hu, et al. · Current Pharmaceutical Biotechnology

Works count: 5

Citation count: 32

H-index: 3

I10-index: 1